文献速递心脑血管急症

机械扩张与自膨胀经导管主动脉瓣置换对高危主动脉瓣狭窄患者死亡率和主要不良临床事件的影响:REPRISE III随机临床试验

Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis: The REPRISE III Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01
一句话结论在高危主动脉瓣狭窄患者中,机械扩张瓣膜对比自膨胀瓣膜在30天主要安全终点和1年主要有效性终点均达到非劣效,且1年中重度瓣周漏更低,但新起搏器植入率更高。

REPRISE III试验在北美、欧洲和澳大利亚55个中心纳入912例高危或极高危、严重症状性主动脉瓣狭窄患者,随机2:1接受机械扩张瓣膜(MEV,607例)或自膨胀瓣膜(SEV,305例)。30天主要安全复合终点MEV组20.3% vs SEV组17.2%,达到非劣效(差值3.1%,Farrington-Manning 97.5%CI -∞至8.3%,非劣效P=.003)。1年主要有效性复合终点MEV组15.4% vs SEV组25.5%,达到非劣效(差值-10.1%,97.5%CI -∞至-4.4%,P<.001),并进一步达到优效(差值-10.2%,95%CI -16.3%至-4.0%,P<.001)。1年中重度瓣周漏MEV组0.9% vs SEV组6.8%(差值-6.1%,95%CI -9.6%至-2.6%,P<.001)。MEV组新起搏器植入率更高(35.5% vs 19.6%,P<.001),瓣膜血栓发生率更高(1.5% vs 0%),但重复操作(0.2% vs 2.0%)、瓣中瓣植入(0% vs 3.7%)和瓣膜位置异常(0% vs 2.7%)更低。

要点

  • 高危主动脉瓣狭窄TAVR患者中,MEV对比SEV的30天主要安全复合终点非劣效:MEV组20.3% vs SEV组17.2%,差值3.1%,97.5%CI -∞至8.3%。
  • 1年主要有效性复合终点MEV组15.4% vs SEV组25.5%,非劣效且优效(差值-10.2%,95%CI -16.3%至-4.0%,P<.001)。
  • 1年中重度瓣周漏MEV组0.9% vs SEV组6.8%,MEV更低(差值-6.1%,95%CI -9.6%至-2.6%,P<.001)。
  • MEV组新起搏器植入率高于SEV组(35.5% vs 19.6%,P<.001),瓣膜血栓MEV组1.5% vs SEV组0%。
  • MEV组重复操作(0.2% vs 2.0%)、瓣中瓣植入(0% vs 3.7%)、瓣膜位置异常(0% vs 2.7%)均低于SEV组。

适用人群与场景

  • 高危或极高危、严重症状性主动脉瓣狭窄患者,平均年龄82.8岁(SD 7.3),女性463例(51%),预测死亡风险6.8%。
  • 研究在北美、欧洲和澳大利亚55个中心开展,纳入时间为2014年9月22日至2015年12月24日,最终随访至2017年3月8日。

诊断标准与关键阈值

  • 主要安全终点非劣效界值10.5%,主要有效性终点非劣效界值9.5%。

研究设计与关键结果

  • 研究类型:随机临床试验(REPRISE III),912例患者随机2:1接受MEV(n=607)或SEV(n=305),874例(96%)在1年时可评估。
  • 30天主要安全复合终点(全因死亡、卒中、危及生命或大出血、2/3期急性肾损伤、主要血管并发症):MEV组20.3% vs SEV组17.2%,差值3.1%,Farrington-Manning 97.5%CI -∞至8.3%,非劣效P=.003。
  • 1年主要有效性复合终点(全因死亡、致残性卒中、中度及以上瓣周漏):MEV组15.4% vs SEV组25.5%,差值-10.1%,Farrington-Manning 97.5%CI -∞至-4.4%,非劣效P<.001。
  • 1年中重度瓣周漏:MEV组0.9% vs SEV组6.8%,差值-6.1%,95%CI -9.6%至-2.6%,P<.001。
  • 主要有效性优效分析:差值-10.2%,95%CI -16.3%至-4.0%,P<.001。
  • 新起搏器植入:MEV组35.5% vs SEV组19.6%,P<.001;瓣膜血栓:MEV组1.5% vs SEV组0%。
  • 重复操作:MEV组0.2% vs SEV组2.0%;瓣中瓣植入:MEV组0% vs SEV组3.7%;瓣膜位置异常:MEV组0% vs SEV组2.7%。

证据类型、等级与局限

  • 证据类型:随机临床试验。
  • 结论:在高危主动脉瓣狭窄患者中,MEV对比SEV在主要安全终点和主要有效性终点均未显示劣效;作者认为MEV可能为高危患者TAVR提供有用的补充。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在高危或极高危严重症状性主动脉瓣狭窄患者中选择TAVR瓣膜类型时,MEV与SEV在30天安全复合终点和1年有效性复合终点上非劣效,MEV的1年中重度瓣周漏更低,但新起搏器植入率更高(35.5% vs 19.6%)。
  • 作者认为MEV可能为高危患者TAVR提供有用的补充。

指南或共识出处

  • REPRISE III随机临床试验(ClinicalTrials.gov Identifier: NCT02202434),发表于JAMA。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Transcatheter aortic valve replacement (TAVR) is established for selected patients with severe aortic stenosis. However, limitations such as suboptimal deployment, conduction disturbances, and paravalvular leak occur.

OBJECTIVE: To evaluate if a mechanically expanded valve (MEV) is noninferior to an approved self-expanding valve (SEV) in high-risk patients with aortic stenosis undergoing TAVR.

DESIGN, SETTING, AND PARTICIPANTS: The REPRISE III trial was conducted in 912 patients with high or extreme risk and severe, symptomatic aortic stenosis at 55 centers in North America, Europe, and Australia between September 22, 2014, and December 24, 2015, with final follow-up on March 8, 2017.

INTERVENTIONS: Participants were randomized in a 2:1 ratio to receive either an MEV (n = 607) or an SEV (n = 305).

MAIN OUTCOMES AND MEASURES: The primary safety end point was the 30-day composite of all-cause mortality, stroke, life-threatening or major bleeding, stage 2/3 acute kidney injury, and major vascular complications tested for noninferiority (margin, 10.5%). The primary effectiveness end point was the 1-year composite of all-cause mortality, disabling stroke, and moderate or greater paravalvular leak tested for noninferiority (margin, 9.5%). If noninferiority criteria were met, the secondary end point of 1-year moderate or greater paravalvular leak was tested for superiority in the full analysis data set.

RESULTS: Among 912 randomized patients (mean age, 82.8 [SD, 7.3] years; 463 [51%] women; predicted risk of mortality, 6.8%), 874 (96%) were evaluable at 1 year. The primary safety composite end point at 30 days occurred in 20.3% of MEV patients and 17.2% of SEV patients (difference, 3.1%; Farrington-Manning 97.5% CI, -∞ to 8.3%; P = .003 for noninferiority). At 1 year, the primary effectiveness composite end point occurred in 15.4% with the MEV and 25.5% with the SEV (difference, -10.1%; Farrington-Manning 97.5% CI, -∞ to -4.4%; P<.001 for noninferiority). The 1-year rates of moderate or severe paravalvular leak were 0.9% for the MEV and 6.8% for the SEV (difference, -6.1%; 95% CI, -9.6% to -2.6%; P < .001). The superiority analysis for primary effectiveness was statistically significant (difference, -10.2%; 95% CI, -16.3% to -4.0%; P < .001). The MEV had higher rates of new pacemaker implants (35.5% vs 19.6%; P < .001) and valve thrombosis (1.5% vs 0%) but lower rates of repeat procedures (0.2% vs 2.0%), valve-in-valve deployments (0% vs 3.7%), and valve malpositioning (0% vs 2.7%).

CONCLUSIONS AND RELEVANCE: Among high-risk patients with aortic stenosis, use of the MEV compared with the SEV did not result in inferior outcomes for the primary safety end point or the primary effectiveness end point. These findings suggest that the MEV may be a useful addition for TAVR in high-risk patients.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02202434.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Feldman TE, Reardon MJ, Rajagopal V, et al. Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis: The REPRISE III Randomized Clinical Trial. JAMA. 2018. PMID: 29297076. doi:10.1001/jama.2017.19132

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。